Introduction
Kaposi's sarcoma associated herpesvirus (KSHV or human herpesvirus 8 ) is a double-stranded DNA gammaherpesvirus associated with KS, primary effusion lymphoma (PEL), and subsets of multicentric Castleman's disease (MCD), an aggressive lymphoproliferative disorder [1] [2] [3] . KSHV predominantly infects B lymphocytes and endothelial cells, and persists as a closed, circular episome expressing few viral genes during latent replication 4 . While KS rates among AIDS patients have dramatically decreased with the use of highly effective antiretroviral therapy 5 , therapeutic options for MCD or PEL are limited and these neoplastic diseases have high mortality rates 1, 6, 7 . Persistent, latent KSHV infection is not amenable to common antiviral drugs targeting the lytic phase herpesvirus-encoded DNA polymerase 8 .
One latent protein, the latency associated nuclear antigen 1 (LANA1) encoded by ORF73 9,10 is consistently expressed in all forms of KS-associated malignancies [11] [12] [13] [14] .
LANA1 tethers the viral episome to cellular chromosomes during mitosis allowing equal segregation of virus genome to daughter cells 12,14-17 . LANA1 is a large nuclear protein with an N-terminal proline-rich domain, an internal glutamine-rich domain and an acidic repeat domain followed by a leucine zipper motif 18, 19 . LANA1 binds through a C-terminal region to two adjacent sites within each KSHV terminal repeat (TR) which acts as the latent origin of replication for the viral episome 20, 21 . LANA1 N-terminal amino acids 5 to 22 form a chromosome binding sequence (CBS) that interacts with chromatin proteins and is sufficient to mediate a specific interaction of LANA1 with chromosomes during mitosis 16, 22, 23 . A second region in the C-terminus (from amino acids 1129 to 1143) has been described as essential for heterochromatin association but is not sufficient alone to mediate this interaction 24, 25 . Thus, by binding the episome through its C-terminal domain and chromosome-associated proteins through its N- Mapping LANA1 epitopes. LANA1 epitopes were mapped using 171 cleavable, biotinylated (N-terminus SGSK) 17-mer peptides offset by 5 amino acids as previously described 36 . Briefly, streptavidin ELISA plates (Roche Applied Science, Indianapolis, IN) were coated with 1.5µg of each peptide. After blocking with 3% BSA/PBS, peptides 5 to 73 (1-357 aa) were incubated with purified scFv BM9 and BM10.
Detection was performed by HRP conjugated anti-HA monoclonal antibody (high affinity 3F10; Roche Applied Science, Indianapolis, IN) at a dilution of 1:3000.
Absorbance was measured on a spectrophotometer (Biophotometer, Eppendorf) at 405nm. SDS-PAGE, and subjected to autoradiography.
For (Fig. 1C) . Despite this evidence for in vitro BM9 scFv binding to LANA1, direct immunoprecipitation of LANA1 using the specific monoclonal antibody CMA-810, followed by immunoblot detection with either BM9 or BM10 failed to detect direct interaction suggesting a weak recognition of the epitope by the scFv. To map anti-LANA1 scFv epitopes, LANA1
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peptide screening using 171 biotinylated peptides was performed by ELISA using the purified BM9 and BM10 scFv, as previously described, to determine dominant epitopes recognized by sera from KSHV-infected patients 36 . BM9 and BM10 (Table I and 
org From compared to the irrelevant control intrabody, 4BL, cloned in the same plasmid backbone (Fig. 4A, B) . This corresponds to dispersion of LANA1 protein expression as depicted by IFA (in red) when anti-LANA1 specific scFvs are expressed (in green) ( Figure 4D) , and confirmed by Western Blot (Figure 4C ). ScFv expression in BC-1 cells has a greater effect in inhibiting cell growth than in BCBL-1. This may indicate that KSHV is the essential oncogenic virus driving these tumors. As previously described, LANA1 has a punctuate nuclear pattern in PEL cells due to the colocalization of Table 2 ). When an irrelevant antibody is expressed no apparent effect is observed in the number of LANA1 chromosomally associated dots. These results strongly correlate with the loss of the TR plasmid when coexpressed with BM9 and BM10, as described above.
For In this study, we generated anti-LANA1 single-chain antibodies from immunized rabbits having weak binding to LANA1. Despite this, both BM9 and BM10
cause episome loss when expressed in KSHV-infected cells. This LANA1
neutralization is most likely to be related to N-terminal specificity for the intrabodies Transfection with the negative control 4BL intrabody has no effect on viral persistence. For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From Table I : Scanning peptide ELISA show that peptides including LANA1 amino acid residues 11-32 (peptides P7-P8) and 11-37 (P7-P9) are bound by BM9 and BM10 respectively, BM9 also showed reactivity to residues 71-87 (P19) and both scFvs reacted to residues 191-207 (P43). Table II . Evaluating dispersion of LANA1 due to scFv expression in BC-1 cells.
LANA1 spots were counted and student ttest were effectuated to statistically compare between scFvs and controls. Student t-tests p-values for average differences, assuming equal variances and unpaired. Two-tailed for among controls or among treatment comparisons and one-tailed for treatment versus controls.
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